Bristol Myers pitches in to Pathios’ $25M Series B for GPCR inhibitor

Pathios Ther­a­peu­tics drew in $25 mil­lion for the first close of a Se­ries B raise that should help the UK biotech test its first-in-class sol­id tu­mor can­di­date in clin­i­cal tri­als by the end of the year.

The raise will al­so be used to ex­pand Pathios, in­clud­ing its ex­ec­u­tive team, “to align with its con­tin­ued evo­lu­tion,” the com­pa­ny said Thurs­day. The biotech was found­ed in 2017 by Tom Mc­Carthy and Alan Nay­lor. It has ap­prox­i­mate­ly 20 staffers, a spokesper­son said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.